Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...
A groundbreaking SAMRC study has uncovered significant underreporting of HIV-related deaths in South Africa, despite the ...
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
A South African Medical Research Council (SAMRC) study has revealed that HIV remains one of the leading causes of death in ...
SAN FRANCISCO — Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that could transform the landscape of HIV prevention.
South Africa Has More People Living With HIV Than Any Other Country. Trump's Aid Freeze Has Hit Hard
KwaZulu-Natal also had the highest number of people living with HIV in South Africa in 2022, about 1.9 million. The country counts more than 7.5 million people infected with the virus that causes ...
In the general population, frailty is an aging-related risk factor for poor outcomes; individuals experiencing frailty face ...
UMZIMKHULU, South Africa — At a rural village in South Africa’s KwaZulu-Natal province, unemployed 19-year-old Nozuko Majola is trying to figure out if she has enough money for the one-hour ...
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback